期刊文献+

健脾活血清热法治疗肝癌

Treatment of Liver Cancer by Strengthening Spleen and Activating Blood Circulation and Heat-clearing Method
下载PDF
导出
摘要 肝癌在我国多发,死亡率高。尽管西医占主导地位,有多种治疗方法,但均存在明显局限。中医能有效弥补西医之不足。在西医治疗的基础上,再予中医配合治疗,能进一步提高疗效。肝癌以脾虚、血瘀和热证多见。健脾活血清热法是肝癌常用治法。该文从多方面介绍了脾虚、血瘀和热证的病因病机,对健脾、活血、清热治法进行了详细分析,强调消灭或控制肝脏癌邪是治疗根本,并附验案1则。 Liver cancer is common in China with high mortality. Although western medicine is still dominant, there are many treatments, all of which have obvious limitations. While traditional Chinese medicine can effectively remedy the deficiency of western medicine. Accompanied with the western medicine treatment, traditional Chinese medicine can further improve the curative effect. Liver cancer is characterized by spleen deficiency, blood stasis and heat syndrome. Strengthening spleen, activating blood circulation and clearing away heat are commonly used therapies for liver cancer. This article introduces the etiology and pathogenesis of spleen deficiency, blood stasis and heat syndrome from many aspects. In this paper,the methods of strengthening spleen, promoting blood circulation and clearing away heat are analyzed in detail. This article emphasizes that the elimination or control of liver cancer is the basis of treatment, and the case 1 is attached to the test.
出处 《中外医疗》 2017年第23期196-198,共3页 China & Foreign Medical Treatment
关键词 健脾 活血 清热 治法 肝癌 Strengthening spleen Activating blood circulation Clearing away heat Therapeutic method Liver cancer
  • 相关文献

参考文献11

二级参考文献97

  • 1侯凤刚,凌昌全,沈旭波,刘庆,岳小强,顾伟,邓哲伟,王喜,贺佳.原发性肝癌中医证型分布文献简析[J].中医杂志,2004,45(11):876-877. 被引量:18
  • 2吴茂林,邓婧,李世杰.癌邪-元气异化学说[J].甘肃中医,2007,20(8):72-73. 被引量:16
  • 3张传光,吴新奎,荆才玉,李凤云.肝动脉栓塞化疗联合口服肝复乐治疗中晚期原发性肝癌56例临床观察[J].实用癌症杂志,2007,22(5):499-500. 被引量:5
  • 4Poon D, Anderson BO, Chen LT, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009 [J]. Lancet Oncol, 2009, 10 ( 11 ) : 1111 - 1118.
  • 5Jordi Bruix,Jean-Luc Raoul,Morris Sherman,Vincenzo Mazzaferro,Luigi Bolondi,Antonio Craxi,Peter R. Galle,Armando Santoro,Michel Beaugrand,Angelo Sangiovanni,Camillo Porta,Guido Gerken,Jorge A. Marrero,Andrea Nadel,Michael Shan,Marius Moscovici,Dimitris Voliotis,Josep M. Llovet.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial[J]. Journal of Hepatology . 2012 (4)
  • 6Josep M. Llovet,Jordi Bruix.Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology . 2003 (2)
  • 7Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncology.2009(1)
  • 8European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma[J].Journal of Hepatology.2012(4)
  • 9Roopinder Gillmore,Sam Stuart,Amy Kirkwood,Ayshea Hameeduddin,Nick Woodward,Andrew K. Burroughs,Tim Meyer.EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization[J].Journal of Hepatology.2011(6)
  • 10Luigi Bolondi,Andrew Burroughs,Jean-Fran?ois Dufour,Peter Galle,Vincenzo Mazzaferro,Fabio Piscaglia,Jean Raoul,Bruno Sangro.Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions[J].Semin Liver Dis.2012(04)

共引文献254

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部